NICE4 Activators
NICE4 Activators encompass a variety of chemical compounds that can enhance the functional activity of NICE4. The majority of these compounds, including Forskolin, IBMX, Rolipram, Epinephrine, PGE2, BAY 60-6583, CGS 21680, and NECA, function by increasing intracellular cAMP levels. They achieve this by either directly activating adenylate cyclase or inhibiting phosphodiesterases, which degrade cAMP. NICE4 is known to be involved in cAMP-dependent pathways, so the increase in cAMP levels can enhance NICE4 activity by promoting its role in these pathways.
On the other hand, the remaining compounds, SQ 22536, ZM 241385, L-858051, and SCH 442416, function by preventing the decrease in cAMP levels. They do this by inhibiting adenylate cyclase or blocking adenosine receptors that when activated, would lead to a reduction in cAMP levels. By preventing the decrease in cAMP levels, these compounds can maintain the involvement of NICE4 in cAMP-dependent pathways, thus enhancing its functional activity. This demonstrates that NICE4 activators can work through several mechanisms to increase cAMP levels
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, enzymes that degrade cAMP. By inhibiting these enzymes, IBMX can raise intracellular cAMP levels, possibly leading to the enhancement of NICE4 functional activity in cAMP-dependent pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective phosphodiesterase-4 inhibitor. By inhibiting PDE4, it increases cAMP levels. In this way, it can enhance NICE4 functional activity by promoting its role in cAMP-dependent pathways. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine is a hormone and neurotransmitter that stimulates adenylate cyclase through the activation of β-adrenergic receptors. This leads to increased cAMP levels, which can enhance NICE4 functional activity in cAMP-dependent pathways. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) activates adenylate cyclase via EP2 and EP4 receptors, leading to increased cAMP levels. This can enhance the functional activity of NICE4 in cAMP-dependent pathways. | ||||||
SQ 22536 | 17318-31-9 | sc-201572 sc-201572A | 5 mg 25 mg | $95.00 $363.00 | 13 | |
SQ 22536 is an adenylate cyclase inhibitor. By preventing the decrease in cAMP levels, it can maintain the role of NICE4 in cAMP-dependent pathways, thus enhancing its functional activity. | ||||||
BAY 60-6583 | 910487-58-0 | sc-503262 | 10 mg | $210.00 | ||
BAY 60-6583 is a selective agonist of adenosine A2B receptor, a G-protein coupled receptor that activates adenylate cyclase, leading to increased cAMP levels. This can enhance NICE4 functional activity in cAMP-dependent pathways. | ||||||
ZM 241385 | 139180-30-6 | sc-361421 sc-361421A | 5 mg 25 mg | $92.00 $356.00 | 1 | |
ZM 241385 is a potent antagonist of the adenosine A2A receptor. By blocking this receptor, it prevents the decrease in cAMP levels, thus enhancing the functional activity of NICE4 in cAMP-dependent pathways. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is a known activator of adenylate cyclase, which leads to increased levels of cAMP. NICE4 is involved in cAMP-dependent pathways, therefore, increased cAMP levels can enhance NICE4 functional activity by promoting its role in these pathways. | ||||||
SCH 442416 | 316173-57-6 | sc-204271 sc-204271A | 1 mg 10 mg | $95.00 $245.00 | 3 | |
SCH 442416 is a selective antagonist of the adenosine A2A receptor. It prevents the decrease in cAMP levels, thereby enhancing the functional activity of NICE4 in cAMP-dependent pathways. | ||||||